230.66 0.00 (0.00%)
After hours: 4:09PM EDT
|Bid||230.74 x 800|
|Ask||237.69 x 1000|
|Day's range||222.85 - 231.32|
|52-week range||119.01 - 285.77|
|Beta (5Y monthly)||0.86|
|PE ratio (TTM)||52.07|
|Earnings date||30 Jul 2020 - 03 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||214.40|
The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Impella RP to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism (PE). Abiomed (NASDAQ: ABMD) manufactures Impella RP.
Abiomed to hold fireside chat at Jefferies Virtual Healthcare Conference.
Data presented at SCAI 2020 demonstrates Impella reduced in-hospital mortality when placed before a non-emergent PCI is performed.
Abiomed (NASDAQ: ABMD), the first company to implant a totally artificial heart in a patient back in 2001, develops technology to help hearts recover. Abiomed's share price vaulted up 31.8% in April, according to data provided by S&P Global Market Intelligence; most of it came at the end of the month, after the company posted heartening results for the fiscal fourth quarter of 2020. For fiscal year 2020, Abiomed reported total revenue of $840.9 million, up 9% year over year compared to 2019 revenue of $769.4 million.
Investors in Abiomed, Inc. (NASDAQ:ABMD) had a good week, as its shares rose 8.9% to close at US$184 following the...
Abiomed (NASDAQ:ABMD) shares have had a really impressive month, gaining 32%, after some slippage. But shareholders...
Shares of Abiomed (NASDAQ: ABMD) were soaring 13.8% higher as of 3:26 p.m. EDT on Thursday. The big jump came after the medical device maker announced its fiscal 2020 fourth-quarter and full-year results before the market opened. Abiomed reported Q4 revenue of $206.7 million, down slightly year over year and narrowly missing the consensus Wall Street revenue estimate of $207.2 million.
Shares of Abiomed (NASDAQ: ABMD), a maker of medical devices that improve heart function, soared after the company announced the acquisition of a company that has developed a portable artificial lung and also reported better-than-expected earnings for its fiscal fourth quarter. In addition, the company reported that its implantable heart pump had been successful in helping a pair of critically ill COVID-19 patients survive the disease. Abiomed has acquired Breethe, a private company that has developed a compact extracorporeal membrane oxygenation (ECMO) system -- an artificial lung for patients suffering from cardiogenic shock or respiratory failure.
Abiomed (NASDAQ: ABMD), maker of the Impella heart pump, has acquired Breethe, developer of a novel extracorporeal membrane oxygenation (ECMO) system that will complement and expand Abiomed’s product portfolio to more comprehensively serve the needs of patients whose lungs can no longer provide sufficient oxygenation, including patients suffering from cardiogenic shock or respiratory failure such as due to ARDS, H1N1, SARS, or COVID-19. ECMO has also been utilized as a primary method of oxygenation and hemodynamic support for pediatric patients.
Abiomed (NASDAQ: ABMD), maker of the Impella heart pump, is taking a number of steps to aid the global medical community and contribute to improved patient care during the COVID-19 outbreak. Impella heart pumps are FDA approved to provide circulatory support to allow the heart to rest and recover for patients suffering from cardiogenic shock, including AMI, right heart failure, cardiomyopathy and myocarditis, or for patients with advanced heart failure undergoing PCI.
A study of 21,848 non-emergent, high-risk patients who underwent percutaneous coronary intervention (PCI) with percutaneous ventricular assist devices (PVADs), including Impella, demonstrates the PVAD patients had a lower rate of mortality and complications than patients who underwent PCI with intra-aortic balloon pumps (IABPs). The study, by Al-khadra, et al., published in the February 15, 2020 print edition of Catheterization & Cardiovascular Interventions.
Abiomed, Inc. (NASDAQ:ABMD) last week reported its latest quarterly results, which makes it a good time for investors...
Today we'll look at Abiomed, Inc. (NASDAQ:ABMD) and reflect on its potential as an investment. To be precise, we'll...
With the 2010s officially drawing to a close, Yahoo Finance took a look at some of the biggest S&P 500 winners and losers of the past decade based on price returns.